NO981662L - Diagnosering av disponerhet for kreft og behandling av dette - Google Patents

Diagnosering av disponerhet for kreft og behandling av dette

Info

Publication number
NO981662L
NO981662L NO981662A NO981662A NO981662L NO 981662 L NO981662 L NO 981662L NO 981662 A NO981662 A NO 981662A NO 981662 A NO981662 A NO 981662A NO 981662 L NO981662 L NO 981662L
Authority
NO
Norway
Prior art keywords
predispositions
diagnosis
cancer
treatment
cancer predispositions
Prior art date
Application number
NO981662A
Other languages
English (en)
Norwegian (no)
Other versions
NO981662D0 (no
Inventor
Kay Nigel Spurr
Christopher Ian Gray
Original Assignee
Imp Cancer Res Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Cancer Res Tech filed Critical Imp Cancer Res Tech
Publication of NO981662D0 publication Critical patent/NO981662D0/no
Publication of NO981662L publication Critical patent/NO981662L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO981662A 1995-10-23 1998-04-14 Diagnosering av disponerhet for kreft og behandling av dette NO981662L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US584095P 1995-10-23 1995-10-23
PCT/GB1996/002588 WO1997015686A1 (en) 1995-10-23 1996-10-22 Diagnosis of susceptibility to cancer and treatment thereof

Publications (2)

Publication Number Publication Date
NO981662D0 NO981662D0 (no) 1998-04-14
NO981662L true NO981662L (no) 1998-06-12

Family

ID=21718018

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981662A NO981662L (no) 1995-10-23 1998-04-14 Diagnosering av disponerhet for kreft og behandling av dette

Country Status (10)

Country Link
EP (1) EP0859860A1 (pt)
JP (1) JP2000500329A (pt)
KR (1) KR19990067011A (pt)
CN (1) CN1203633A (pt)
AU (1) AU722266B2 (pt)
BR (1) BR9611255A (pt)
CA (1) CA2232241A1 (pt)
NO (1) NO981662L (pt)
NZ (1) NZ320425A (pt)
WO (1) WO1997015686A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287854B1 (en) 1996-10-22 2001-09-11 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
US6262242B1 (en) * 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
AU4188499A (en) * 1998-05-14 1999-11-29 University Of Virginia Patent Foundation Isolation and use of fetal urogenital sinus expressed sequences
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
GB9903841D0 (en) 1999-02-20 1999-04-14 Imp College Innovations Ltd Diagnosis and treatment of cancer
FR2810677B1 (fr) * 2000-06-27 2004-10-01 Urogene Procede de diagnostic in vitro du cancer de la prostate et kit de mise en oeuvre
CN119061128B (zh) * 2024-11-06 2025-04-18 海南大学三亚南繁研究院 一种微卫星dna扩增引物对及二代测序方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2013430A1 (en) * 1990-03-29 1991-09-29 Michael Litt Method for identifying human subjects by analysis of genetic material
GB9307754D0 (en) * 1993-04-15 1993-06-02 Perry Robert E Diagnostic probes and therapeutic products
US5670314A (en) * 1994-02-22 1997-09-23 Regents Of The University Of California Genetic alterations that correlate with lung carcinomas
CA2170627A1 (en) * 1994-05-20 1995-11-30 Robert Bookstein A novel prostate/colon tumor suppressor gene located on human chromosome 8

Also Published As

Publication number Publication date
AU7316196A (en) 1997-05-15
NZ320425A (en) 2001-03-30
AU722266B2 (en) 2000-07-27
NO981662D0 (no) 1998-04-14
CA2232241A1 (en) 1997-05-01
WO1997015686A1 (en) 1997-05-01
EP0859860A1 (en) 1998-08-26
CN1203633A (zh) 1998-12-30
JP2000500329A (ja) 2000-01-18
KR19990067011A (ko) 1999-08-16
BR9611255A (pt) 1999-12-28

Similar Documents

Publication Publication Date Title
NO971015D0 (no) Forbindelser og metoder for behandling av cancer
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
FI970990A7 (fi) Syövän toteaminen ja hoito
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
NO976063D0 (no) Fremgangsmåte for behandling av diabetes
FI964874A0 (fi) Vihannesten käsittely
KR970000051A (ko) 카카오의 효소 처리법
NO970532D0 (no) System og metode for blodbehandling
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
NO965563D0 (no) Behandling og profylakse av osteoporese
NO20002189L (no) Anvendelse av makrolider for behandling av cancer og mukuladegenerasjon
EP0883809A4 (en) METHOD FOR DIAGNOSTIC PROSTATE ADENOCARCINOMAS
NO965564D0 (no) Medisinsk anvendelse av bromelain
NO981662D0 (no) Diagnosering av disponerhet for kreft og behandling av dette
NO994631D0 (no) Fremgangsmaater og sammensetninger for behandling av eggstokkreft
GB9811598D0 (en) Diagnosis and treatment of cancer
NO973193D0 (no) Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
NO981822D0 (no) Anvendelse av proteinet GAX for behandling av cancer
NO982582D0 (no) FremgangsmÕte for behandling av smerte
NO961113D0 (no) Behandling og forebyggelse av prostatakreft
NO982562D0 (no) Sammensetning for behandling av smerte
NO20003915L (no) Topiramat og beslektede derivater for behandling av schizofreni
NO963482D0 (no) Medisinsk anvendelse av bromelain

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application